<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551707</url>
  </required_header>
  <id_info>
    <org_study_id>CRx-102-007</org_study_id>
    <nct_id>NCT00551707</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis</brief_title>
  <acronym>MARS-1</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zalicus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zalicus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug
      dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to
      work through a novel mechanism of action in which dipyridamole selectively amplifies the
      anti-inflammatory and immunomodulatory activities of the glucocorticoid without replicating
      the dose-dependent adverse effects. CRx-102 has been associated with clinical benefit in
      proof of concept studies in subjects with hand Osteoarthritis (OA) and Rheumatoid Arthritis
      (RA).

      In this trial, CRx-102 will be given to subjects with active RA as an add-on therapy to
      existing stable doses of Disease Modifying Anti-Rheumatic Drugs (DMARDs) including
      methotrexate (MTX), sulfasalazine, hydroxychloroquine, leflunomide or azathioprine. MTX in
      combination with other DMARDs (e.g., sulfasalazine or hydroxychloroquine) will be permitted
      to reflect the current standard of care practices within rheumatology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was discontinued before the enrollment objective was met. Preliminary review of the
      efficacy dataset revealed that the efficacy dataset was not robust enough to support an
      extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values
      over time and the percent change in C-reactive protein (CRP) values in the As-Treated
      population were calculated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population</measure>
    <time_frame>Day 98</time_frame>
    <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Day 98 in C-reactive Protein (CRP) Values - As Treated Population</measure>
    <time_frame>baseline to day 98</time_frame>
    <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Superiority of CRx-102 Compared to Prednisolone and Dipyridamole Using American College of Rheumatology Rating Scale (20% or More Improvement; ACR20) Calculated From Baseline to Day 98 in Subjects With Active Rheumatoid Arthritis</measure>
    <time_frame>baseline to day 98</time_frame>
    <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Efficacy of CRx-102 Compared to Placebo Using ACR 20 Calculated From Baseline to Day 98</measure>
    <time_frame>baseline to 98 Days</time_frame>
    <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CRx-102 (2.7/180)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRx-102 (2.7/360)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo administered twice per day at 8 AM and 1 PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRx-102 (2.7/180)</intervention_name>
    <description>prednisolone 2.7 mg plus dipyridamole 180 mg</description>
    <arm_group_label>CRx-102 (2.7/180)</arm_group_label>
    <arm_group_label>CRx-102 (2.7/360)</arm_group_label>
    <other_name>prednisolone 2.7 mg plus dipyridamole 180 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>prednisolone (2.7 mg)</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyridamole</intervention_name>
    <description>dipyridamole 360 mg</description>
    <arm_group_label>Dipyridamole</arm_group_label>
    <other_name>dipyridamole 360 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRx-102 (2.7/360)</intervention_name>
    <description>Prednisolone 2.7 mg plus Dipyridamole 360 mg</description>
    <arm_group_label>CRx-102 (2.7/360)</arm_group_label>
    <other_name>Prednisolone 2.7 mg plus Dipyridamole 360 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must voluntarily give written informed consent

          -  Subject must be ≥ 18 years of age

          -  Subject must have RA (ACR criteria)

          -  Subject must have at least 4 swollen joints and at least 6 tender joints at screening
             and baseline (28 joint count)

          -  Subject must have a CRP &gt; Upper Limit of Normal at screening

          -  Subject must have been on DMARD or DMARD combination (e.g. MTX + hydroxychloroquine)
             for at least 3 months and be on a stable dose of DMARD(s) for at least 6 weeks prior
             to screening.

          -  For MTX subjects: MTX ≥ 7.5 mg weekly (po/sc/im) and willing to take folic acid or
             folinic acid supplementation

          -  Subject willing to take concomitant multivitamin or the equivalent of 400 I.U. vitamin
             D and the equivalent of 1000 mg of elemental calcium daily

        Exclusion Criteria:

          -  History of clinically significant (as determined by the Investigator) cardiac,
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
             neurologic, dermatologic, psychiatric, renal, and/or other major disease

          -  Wheelchair or bed bound

          -  History of osteoporotic fracture

          -  History of malignancy within the past 10 years. However, subjects with a history of
             treated or excised basal cell carcinoma or fewer than 3 squamous cell carcinomas are
             eligible to participate

          -  History of lymphoma or chronic leukemia

          -  Moles or lesions that are currently undiagnosed, but are suspicious for malignancy

          -  Surgery within the previous 3 months (except for minor dental and cosmetic)

          -  History of drug or alcohol abuse (as defined by the Investigator)

          -  History of bleeding disorder

          -  History of gastrointestinal bleeding within 5 years of screening

          -  History of severe migraines or headaches

          -  History of glaucoma

          -  Active diabetic retinopathy

          -  Visually compromising cataract

          -  History of opportunistic infection within the previous 12 months

          -  Active Tuberculosis (TB)

          -  Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,
             septicemia) within 3 months prior to screening

          -  Fever or symptomatic viral or bacterial infection within 2 weeks prior to screening

          -  Positive for Hepatitis C virus (HCV) antibody

          -  Positive for HBsAg

          -  Known positive HIV antibody

          -  Has a history of hypersensitivity to glucocorticoids and/or dipyridamole

          -  Treatment with oral, intra-articular, intramuscular, or intravenous glucocorticoids
             within 6 weeks prior to screening; inhaled glucocorticoid is permitted

          -  Treatment with any tumor necrosis factor-alpha (TNFα) biologic, anakinra or abatacept
             within 2 months prior to screening

          -  Treatment with rituximab

          -  Treatment with another investigational drug 3 months prior to screening

          -  Treatment with anticoagulants including: dipyridamole, warfarin, clopidogrel,
             ticlopidine; Acetylsalicylic acid &gt; 150 mg per day

          -  Treatment with any concomitant medications that have not been at a stable dose for at
             least 28 days prior to screening

          -  Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) laboratory values
             that exceed 1.5 x ULN

          -  HbA1C value of &gt; 7.0%

          -  Current enrollment in any other study with investigational drug or device

          -  Female subject who is pregnant or lactating or of child bearing potential and not
             using acceptable methods of contraception (birth control pills, barriers or
             abstinence)

          -  Unwilling or unable to comply with the requirements of this protocol, including the
             presence of any condition (physical, mental, or social) that is likely to affect the
             subject's return for follow-up visits on schedule

          -  Other unspecified reasons that, in the opinion of the Investigator or sponsor make the
             subject unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zalicus</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esztergom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguas Calientes</city>
        <state>Aguascalientes</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vallarta Norte</city>
        <state>Guadalajara</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <results_first_submitted>February 10, 2014</results_first_submitted>
  <results_first_submitted_qc>March 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2014</results_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CombinatoRx</keyword>
  <keyword>CRx-102</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Dipyridamole</keyword>
  <keyword>ACR20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CRx-102 (2.7/180)</title>
          <description>CRx-102 dose 1 2.7 mg prednisolone plus 180 mg dipyridamole</description>
        </group>
        <group group_id="P2">
          <title>CRx-102 (2.7/360)</title>
          <description>Crx-102 (Dose 2)
2.7 mg prednisolone plus 360 mg dipyridamole</description>
        </group>
        <group group_id="P3">
          <title>Prednisolone</title>
          <description>prednisolone
prednisolone: prednisolone (2.7 mg)</description>
        </group>
        <group group_id="P4">
          <title>Dipyridamole</title>
          <description>dipyridamole
dipyridamole: dipyridamole (360 mg)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>placebo
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CRx-102 (2.7/180)</title>
          <description>Crx-102 (Dose 1) 2.7 mg prednisolone plus 180 mg dipyridamole</description>
        </group>
        <group group_id="B2">
          <title>CRx-102 (2.7/360)</title>
          <description>Crx-102 (Dose 2)
2.7 mg prednisolone plus 360 mg dipyridamole</description>
        </group>
        <group group_id="B3">
          <title>Prednisolone</title>
          <description>prednisolone
prednisolone: prednisolone (2.7 mg)</description>
        </group>
        <group group_id="B4">
          <title>Dipyridamole</title>
          <description>dipyridamole
dipyridamole: dipyridamole (180 mg or 360 mg)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>placebo
placebo: placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="5.50"/>
                    <measurement group_id="B2" value="56.2" spread="11.96"/>
                    <measurement group_id="B3" value="55.8" spread="11.32"/>
                    <measurement group_id="B4" value="56.5" spread="12.76"/>
                    <measurement group_id="B5" value="58.8" spread="9.54"/>
                    <measurement group_id="B6" value="56.0" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Day 98 in C-reactive Protein (CRP) Values - As Treated Population</title>
        <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
        <time_frame>baseline to day 98</time_frame>
        <population>As treated population</population>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 (2.7/180)</title>
            <description>CRx-102 dose 1 2.7 mg prednisolone plus 180 mg dipyridamole</description>
          </group>
          <group group_id="O2">
            <title>CRx-102 (2.7/360)</title>
            <description>Crx-102 (Dose 2)
2.7 mg prednisolone plus 360 mg dipyridamole</description>
          </group>
          <group group_id="O3">
            <title>Prednisolone</title>
            <description>prednisolone
prednisolone: prednisolone (2.7 mg)</description>
          </group>
          <group group_id="O4">
            <title>Dipyridamole</title>
            <description>dipyridamole
dipyridamole: dipyridamole (360 mg)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Day 98 in C-reactive Protein (CRP) Values - As Treated Population</title>
          <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
          <population>As treated population</population>
          <units>percentage of change from baseline</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.90" spread="18.45" lower_limit="-36.1" upper_limit="3.8"/>
                    <measurement group_id="O2" value="-40.84" spread="66.80" lower_limit="-95.9" upper_limit="148.1"/>
                    <measurement group_id="O3" value="15.92" spread="1453.54" lower_limit="-80.6" upper_limit="4617.6"/>
                    <measurement group_id="O4" value="-33.67" spread="30.43" lower_limit="-54.4" upper_limit="15.0"/>
                    <measurement group_id="O5" value="-27.64" lower_limit="-35.0" upper_limit="203.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Superiority of CRx-102 Compared to Prednisolone and Dipyridamole Using American College of Rheumatology Rating Scale (20% or More Improvement; ACR20) Calculated From Baseline to Day 98 in Subjects With Active Rheumatoid Arthritis</title>
        <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
        <time_frame>baseline to day 98</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population</title>
        <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
        <time_frame>Day 98</time_frame>
        <population>As treated population</population>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 (2.7/180)</title>
            <description>Crx-102 (Dose 1)
2.7 mg prednisolone plus 180 mg dipyridamole</description>
          </group>
          <group group_id="O2">
            <title>CRx-102 (2.7/360)</title>
            <description>Crx-102 (Dose 2)
2.7 mg prednisolone plus 360 mg dipyridamole</description>
          </group>
          <group group_id="O3">
            <title>Prednisolone</title>
            <description>prednisolone
prednisolone: prednisolone (2.7 mg)</description>
          </group>
          <group group_id="O4">
            <title>Dipyridamole</title>
            <description>dipyridamole
dipyridamole: dipyridamole 360 mg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute C-reactive Protein (CRP) Values at Day 98 - As Treated Population</title>
          <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
          <population>As treated population</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.85" spread="5.39" lower_limit="6.6" upper_limit="18.9"/>
                    <measurement group_id="O2" value="14.25" spread="15.52" lower_limit="1.1" upper_limit="48.0"/>
                    <measurement group_id="O3" value="21.85" spread="27.10" lower_limit="1.2" upper_limit="80.2"/>
                    <measurement group_id="O4" value="16.60" spread="16.22" lower_limit="15.9" upper_limit="48.8"/>
                    <measurement group_id="O5" value="2.68" spread="4.88" lower_limit="0.9" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Efficacy of CRx-102 Compared to Placebo Using ACR 20 Calculated From Baseline to Day 98</title>
        <description>Preliminary review of the efficacy dataset revealed that the efficacy dataset was not robust enough to support an extensive formal efficacy analysis as described in the SAP. Therefore, only the CRP values over time and the percent change in CRP values in the As-Treated population were calculated.</description>
        <time_frame>baseline to 98 Days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From subject entry into the study (defined as the time at which the informed consent form was signed) to the end of study visit at day 98</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRx-102 (Dose 1)</title>
          <description>Crx-102 (Dose 1)
CRx-102: prednisolone + dipyridamole</description>
        </group>
        <group group_id="E2">
          <title>CRx-102 (Dose 2)</title>
          <description>Crx-102 (Dose 2)
CRx-102: prednisolone + dipyridamole</description>
        </group>
        <group group_id="E3">
          <title>Prednisolone</title>
          <description>prednisolone
prednisolone: prednisolone (2.7 mg)</description>
        </group>
        <group group_id="E4">
          <title>Dipyridamole</title>
          <description>dipyridamole
dipyridamole: dipyridamole (180 mg or 360 mg)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>placebo
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret Lee, PhD</name_or_title>
      <organization>Zalicus</organization>
      <phone>617-301-7142</phone>
      <email>mlee@zalicus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

